Skip to main navigation Skip to search Skip to main content

A Phase 2, randomized, partially blinded, controlled, dose-ranging study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of VEL-101 in kidney transplant recipients (LIBERATE)

Project: Research

Project Details

StatusActive
Effective start/end date07/28/26 → 12/31/27

Funding

  • Veloxis Pharmaceuticals Incorporated: $6,604.00